Molecular and translational advances in meningiomas

International Consortium on Meningiomas

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.

Original languageEnglish (US)
Pages (from-to)I4-I17
JournalNeuro-oncology
Volume21
DOIs
StatePublished - Jan 14 2019

Fingerprint

Meningioma
Clinical Trials
Epigenomics
Neoplasms
Therapeutics
Brain Neoplasms
Radiotherapy
Animal Models

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

International Consortium on Meningiomas. / Molecular and translational advances in meningiomas. In: Neuro-oncology. 2019 ; Vol. 21. pp. I4-I17.
@article{d047cc2facba40c1937060105adefa81,
title = "Molecular and translational advances in meningiomas",
abstract = "Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.",
author = "{International Consortium on Meningiomas} and Suganth Suppiah and Farshad Nassiri and Bi, {Wenya Linda} and Dunn, {Ian F.} and Hanemann, {Clemens Oliver} and Horbinski, {Craig M.} and Rintaro Hashizume and James, {Charles David} and Christian Mawrin and Houtan Noushmehr and Arie Perry and Felix Sahm and Andrew Sloan and {Von Deimling}, Andreas and Wen, {Patrick Y.} and Kenneth Aldape and Gelareh Zadeh and Karolyn Au and Jill Barnhartz-Sloan and Brastianos, {Priscilla K.} and Nicholas Butowski and Carlos Carlotti and Cusimano, {Michael D.} and Francesco Dimeco and Katharine Drummond and Evanthia Galanis and Caterina Giannini and Roland Goldbrunner and Brent Griffith and Hanemann, {C. Oliver} and Christel Herold-Mende and Huang, {Raymond Y.} and David James and Jenkinson, {Michael D.} and Christine Jungk and Kaufman, {Timothy J.} and Boris Krischek and Daniel Lachance and Christian Lafoug{\`e}re and Ian Lee and Liu, {Jeff C.} and Yasin Mamatjan and Alireza Mansouri and Michael McDermott and David Munoz and Ng, {Ho Keung} and Farhad Pirouzmand and Poisson, {Laila M.} and Bianca Pollo and David Raleigh",
year = "2019",
month = "1",
day = "14",
doi = "10.1093/neuonc/noy178",
language = "English (US)",
volume = "21",
pages = "I4--I17",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",

}

International Consortium on Meningiomas 2019, 'Molecular and translational advances in meningiomas', Neuro-oncology, vol. 21, pp. I4-I17. https://doi.org/10.1093/neuonc/noy178

Molecular and translational advances in meningiomas. / International Consortium on Meningiomas.

In: Neuro-oncology, Vol. 21, 14.01.2019, p. I4-I17.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular and translational advances in meningiomas

AU - International Consortium on Meningiomas

AU - Suppiah, Suganth

AU - Nassiri, Farshad

AU - Bi, Wenya Linda

AU - Dunn, Ian F.

AU - Hanemann, Clemens Oliver

AU - Horbinski, Craig M.

AU - Hashizume, Rintaro

AU - James, Charles David

AU - Mawrin, Christian

AU - Noushmehr, Houtan

AU - Perry, Arie

AU - Sahm, Felix

AU - Sloan, Andrew

AU - Von Deimling, Andreas

AU - Wen, Patrick Y.

AU - Aldape, Kenneth

AU - Zadeh, Gelareh

AU - Au, Karolyn

AU - Barnhartz-Sloan, Jill

AU - Brastianos, Priscilla K.

AU - Butowski, Nicholas

AU - Carlotti, Carlos

AU - Cusimano, Michael D.

AU - Dimeco, Francesco

AU - Drummond, Katharine

AU - Galanis, Evanthia

AU - Giannini, Caterina

AU - Goldbrunner, Roland

AU - Griffith, Brent

AU - Hanemann, C. Oliver

AU - Herold-Mende, Christel

AU - Huang, Raymond Y.

AU - James, David

AU - Jenkinson, Michael D.

AU - Jungk, Christine

AU - Kaufman, Timothy J.

AU - Krischek, Boris

AU - Lachance, Daniel

AU - Lafougère, Christian

AU - Lee, Ian

AU - Liu, Jeff C.

AU - Mamatjan, Yasin

AU - Mansouri, Alireza

AU - McDermott, Michael

AU - Munoz, David

AU - Ng, Ho Keung

AU - Pirouzmand, Farhad

AU - Poisson, Laila M.

AU - Pollo, Bianca

AU - Raleigh, David

PY - 2019/1/14

Y1 - 2019/1/14

N2 - Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.

AB - Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treatment options for symptomatic meningiomas are limited to surgical resection where possible and adjuvant radiation therapy for tumors with concerning histopathological features or recurrent disease. At present, alternative adjuvant treatment options are not available in part due to limited historical biological analysis and clinical trial investigation on meningiomas. With advances in molecular and genomic techniques in the last decade, we have witnessed a surge of interest in understanding the genomic and epigenomic landscape of meningiomas. The field is now at the stage to adopt this molecular knowledge to refine meningioma classification and introduce molecular algorithms that can guide prediction and therapeutics for this tumor type. Animal models that recapitulate meningiomas faithfully are in critical need to test new therapeutics to facilitate rapid-cycle translation to clinical trials. Here we review the most up-to-date knowledge of molecular alterations that provide insight into meningioma behavior and are ready for application to clinical trial investigation, and highlight the landscape of available preclinical models in meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=85060044130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060044130&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy178

DO - 10.1093/neuonc/noy178

M3 - Article

C2 - 30649490

AN - SCOPUS:85060044130

VL - 21

SP - I4-I17

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -

International Consortium on Meningiomas. Molecular and translational advances in meningiomas. Neuro-oncology. 2019 Jan 14;21:I4-I17. https://doi.org/10.1093/neuonc/noy178